Optimization of lipid nanoparticles for CRISPR/Cas9 delivery: a strategy for enhanced gene editing in a lung tumor model
10AM EDT | May 19, 2026
Lung cancer remains one of the leading causes of cancer-related deaths globally, making it imperative to develop more effective therapies. KRAS mutations are found in a significant percentage of lung cancer cases, presenting a particularly challenging target due to their complex nature. Traditional treatment strategies often fall short, highlighting the urgent need for innovative approaches to precisely target and treat these mutations.
We are excited to invite Dr. Simone Pinto Carneiro to present her pioneering research on using CRISPR/Cas9 gene editing delivered via lipid nanoparticles (LNPs) for lung cancer treatment.
In this webinar, Dr. Carneiro will introduce her team's work on optimizing lipid nanoparticles (LNPs) to enhance the delivery and effectiveness of CRISPR/Cas9 for targeting KRAS mutations in lung tumors. She will guide us through the process of LNP formulation optimization, including formulation screening, physicochemical characterization, and rigorous in vitro and in vivo safety and efficacy assessments.
Key points to be discussed during the session:
- How optimizing lipid nanoparticles (LNPs) can significantly improve CRISPR/Cas9 gene editing efficiency and targeting of KRAS mutations
- The strategic potential of CRISPR/Cas9-LNPs for precise mutation-specific targeting in lung cancer models
- The promise of CRISPR/Cas9-LNPs as inhalable therapeutics, providing a non-invasive, localized approach to treat lung tumors
Speaker
Simone Pinto Carneiro, PhD
Group Leader, Ludwig-Maximilians-University of Munich
Dr. Simone Carneiro is a pharmacist by training and holds a PhD in Biotechnology from the Federal University of Ouro Preto, Brazil. With over 13 years of experience in developing novel drug delivery systems for gene therapy, she specializes in RNA-lipid nanoparticles for pulmonary applications. She has contributed to 20 high-impact publications and co-authored 3 patents, demonstrating her innovative research in RNA therapeutics. As a Group Leader at Ludwig-Maximilians-University of Munich, she leads a team advancing non-viral RNA delivery strategies in collaboration with academia and industry. Having conducted research across three countries, Simone Carneiro is committed to translating innovative RNA technologies into impactful therapeutic solutions.
